Tibor Kovacsovics,
MD
Languages Spoken: English, French, German
Dr. Tibor Kovacsovics started at the University of Utah/Huntsman Cancer Institute in 2013. He focuses on hematologic malignancies, particularly acute leukemias. He serves as the Medical Director for the Inpatient Service of the Division of Hematology and Hematologic Malignancies. In his role as Associate Director of Hematologic Malignancy Clinical Research in the HCI Clinical Trials Office, he has established a phase 1 program in hematologic malignancies, coordinated clinical research in the Division and developed a Clinical-translational Research Network suitable to carry out multicenter investigator-initiated studies in hematologic malignancies, with an emphasis on correlative science. He has also developed relationships with community practices to engage community practices in HCI-based clinical trials and increase the number of patients treated on clinical trials.
Clinical Locations
Hematology Clinic
801-585-2626
Clinic 2C/BMT, Blood and Marrow Transplant
801-585-2626
Fax: (801) 585-3854
Specialties
Board Certification and Academic Information
| Academic Departments | Internal Medicine
-
Professor (Clinical) |
| Academic Divisions | Hematology/BMT |
Patient Rating
The Patient Rating score is an average of all responses to care provider related questions on our nationally-recognized Press Ganey Patient Satisfaction Survey.
Responses are measured on a scale of 1 to 5 with 5 being the best score.
Likelihood of recommending care provider
4.8/ 5
Care provider's explanation of condition/problem
4.8/ 5
Care provider's effort to include me in decisions
4.7/ 5
Wait time at clinic
4.0/ 5
Care provider's concern for questions & worries
4.8/ 5
Patient Comments
Patient comments are gathered from our Press Ganey Patient Satisfaction Survery and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.
UofU Patient
November 16, 2021
HUNTSMAN CANCER CENTER
Excellent experience
UofU Patient
November 14, 2021
HUNTSMAN CANCER CENTER
Could not ask for a better doctor!!!
UofU Patient
November 10, 2021
HUNTSMAN CANCER CENTER
I dont believe and would be answering this survey today, if it was not for Dr. K and his staff
UofU Patient
October 10, 2021
HUNTSMAN CANCER CENTER
Learned important information about my condition and a treatment plan was arranged. A social worker helped find housing for a needed stay in SLC.
UofU Patient
October 07, 2021
HUNTSMAN CANCER CENTER
Dr. K is always kind and attentive to me, even when I may not do the procedure he recommends.
UofU Patient
October 03, 2021
HUNTSMAN CANCER CENTER
Huntsman is the best, all the people there.
UofU Patient
July 31, 2021
HUNTSMAN CANCER CENTER
Dr. Kovacsovics explained the results of my last biopsy and what that meant. He also outlined my continued follow-up care in a clear manner so that I had no questions about what happens next. I chose Dr. Kovacsovics to be my physician after I met him during my hospitalization. I have never been unhappy with that decision. I believe he has given me a " rest of my life" to look forward to.
UofU Patient
July 18, 2021
HUNTSMAN CANCER CENTER
Dr. K is the best
UofU Patient
June 23, 2021
HUNTSMAN CANCER CENTER
Grace and Dr. Kovacsovics ar very thorough and clear in explaining test results and next steps in treatment. Excellent team.
UofU Patient
May 27, 2021
HUNTSMAN CANCER CENTER
Very thorough and very capable discussions. Dr. Kovacsovics pointed out the important aspects of my response to treatment very concisely.
UofU Patient
May 23, 2021
HUNTSMAN CANCER CENTER
I am always impressed how kind and friendly Dr K is! We love having him as my doctor! We know that I'm in good hands with him.
UofU Patient
March 26, 2021
HUNTSMAN CANCER CENTER
Dr. K and staff are fantastic!
UofU Patient
March 04, 2021
HUNTSMAN CANCER CENTER
Dr. K is very interested and caring. I feel my providers are doing the best they can, and I feel they really care about my condition.
UofU Patient
February 25, 2021
HUNTSMAN CANCER CENTER
I felt cared for and informed,
UofU Patient
February 07, 2021
HUNTSMAN CANCER CENTER
Jan Weidner is so great with explanations.
UofU Patient
December 20, 2020
HUNTSMAN CANCER CENTER
They explained what they knew so far, but kept me calm and relaxed by not speculating on one particular outcome without all the test results at hand. They looked at the whole picture, I felt validated and heard.
UofU Patient
December 20, 2020
HUNTSMAN CANCER CENTER
time for me to start treatment. I didn't want to hear that news but have complete confidence in Dr K and his staff.
UofU Patient
October 12, 2020
HUNTSMAN CANCER CENTER
The staff is the best I have ever had.
UofU Patient
October 07, 2020
HUNTSMAN CANCER CENTER
dr. Kovasavics is communicative, caring, professional in every way. excellent physician
UofU Patient
September 04, 2020
HUNTSMAN CANCER CENTER
The physicians assistant did n=all of the routine checking and questions. Dr. K just came in after they consulted with each other and talked about his feelings about my condition.
UofU Patient
August 14, 2020
HUNTSMAN CANCER CENTER
Dr. K is the best....love himKlasina is awesome...
UofU Patient
July 15, 2020
HUNTSMAN CANCER CENTER
I have a great team
UofU Patient
July 12, 2020
HUNTSMAN CANCER CENTER
They treated me with the upmost respect and concern.
UofU Patient
June 09, 2020
HUNTSMAN CANCER CENTER
wonderful experience
UofU Patient
June 04, 2020
HUNTSMAN CANCER CENTER
I would highly recommend Huntsman to anyone who needs cancer treatment
UofU Patient
May 20, 2020
HUNTSMAN CANCER CENTER
Dr. Kovacsovics and Jan Weidner work well together as a team. Dr Kovacsovics is without question the best physician//health. care provider I have had in my lifetime.
UofU Patient
April 27, 2020
HUNTSMAN CANCER CENTER
my team at Huntsman is absolutely the best. I feel safe and secure with my life in their hands. I know they will always do their best.
UofU Patient
February 17, 2020
HUNTSMAN CANCER CENTER
great team that works well together to meet patient needs
UofU Patient
February 14, 2020
HUNTSMAN CANCER CENTER
VerRy good
UofU Patient
February 11, 2020
HUNTSMAN CANCER CENTER
Dr. K is always very caring and communicative about my care.
UofU Patient
January 27, 2020
HUNTSMAN CANCER CENTER
Dr. Kovasavics and PA Jan Weidner are patient-centered, knowledgeable and very accessible in explaining my current condition, test results and next steps in treatment. I couldn't be more pleased with the level of care that I am receiving from my Huntsman Cancer team. my experiences are always informative, positive and caring.
Dr. Tibor Kovacsovics started at the University of Utah/Huntsman Cancer Institute in 2013. He focuses on hematologic malignancies, particularly acute leukemias. He serves as the Medical Director for the Inpatient Service of the Division of Hematology and Hematologic Malignancies. In his role as Associate Director of Hematologic Malignancy Clinical Research in the HCI Clinical Trials Office, he has established a phase 1 program in hematologic malignancies, coordinated clinical research in the Division and developed a Clinical-translational Research Network suitable to carry out multicenter investigator-initiated studies in hematologic malignancies, with an emphasis on correlative science. He has also developed relationships with community practices to engage community practices in HCI-based clinical trials and increase the number of patients treated on clinical trials.
Academic Locations
Board Certification and Academic Information
| Academic Departments | Internal Medicine
-
Professor (Clinical) |
| Academic Divisions | Hematology/BMT |
Research Interests
- Acute Myeloid Leukemia (AML)
- Acute Lymphoblastic Leukemia
- Chemotherapy
- Hematopoietic Stem Cell Transplantation
Education History
| Fellowship | Brigham and Women's Hospital Clinical and Research Fellow in Medicine, Hematology-Oncology Clinical Fellow, 1994 |
| Fellowship | Massachusetts General Hospital Clinical and Research Fellow in Medicine, Hematology-Oncology Clinical Fellow, 1991 |
| Chief Resident | Clinique Médicale Thérapeutique, Geneva University Hospital Internal Medicine Chief Resident, 1990 |
| Residency | Clinique Médicale Thérapeutique, Geneva University Hospital Internal Medicine Resident, 1988 |
| Postdoctoral Fellowship | University of Lausanne Research Assistant, Institute of Biochemistry Postdoctoral Fellow, 1985 |
| Professional Medical | University of Geneva Medical School Medicine M.D., 1981 |
Selected Publications - Journal Articles
Journal Article
- Alsina M, Landgren O, Raje N, Niesvizky R, Bensinger WI, Berdeja JG, Kovacsovics T, Vesole DH, Fang B, Kimball AS, Siegel DS (2020). A phase 1b study of once-weekly carfilzomib combined with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma. Am J Hematol, 96(2), 226-233.
- Burd A, Levine RL, Ruppert AS, Mims AS, Borate U, Stein EM, Patel P, Baer MR, Stock W, Deininger M, Blum W, Schiller G, Olin R, Litzow M, Foran J, Lin TL, Ball B, Boyiadzis M, Traer E, Odenike O, Arellano M, Walker A, Duong VH, Kovacsovics T, Collins R, Shoben AB, Heerema NA, Foster MC, Vergilio JA, Brennan T, Vietz C, Severson E, Miller M, Rosenberg L, Marcus S, Yocum A, Chen T, Stefanos M, Druker B, Byrd JC (2020). Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial. Nat Med, 26(12), 1852-1858.
- Patel AB, Pomicter AD, Yan D, Eiring AM, Antelope O, Schumacher JA, Kelley TW, Tantravahi SK, Kovacsovics TJ, Shami PJ, OHare T, Deininger MW (2020). Dasatinib overcomes stroma-based resistance to the FLT3 inhibitor quizartinib using multiple mechanisms. Leukemia, 34(11), 2981-2991.
- Pregenzer-Wenzler A, Abraham J, Barrell K, Kovacsovics T, Nativi-Nicolau J (2020). Utility of Biomarkers in Cardiac Amyloidosis. JACC Heart Fail, 8(9), 701-711.
- Palladini G, Kastritis E, Maurer MS, Zonder J, Minnema MC, Wechalekar AD, Jaccard A, Lee HC, Bumma N, Kaufman JL, Medvedova E, Kovacsovics T, Rosenzweig M, Sanchorawala V, Qin X, Vasey SY, Weiss BM, Vermeulen J, Merlini G, Comenzo RL (2019). Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA. Blood, 136(1), 71-80.
- Willis C, Menon J, Unni S, Au T, Yoo M, Biskupiak J, Brixner D, Ndife B, Joseph G, Bonifacio G, Stein E, Tantravahi S, Shami PJ, Kovacsovics T, Stenehjem D (2019). Clinical and economic analysis of patients with acute myeloid leukemia by FLT3 status and midostaurin use at a Comprehensive Cancer Center. Leuk Res, 87, 106262.
- Biran N, Siegel D, Berdeja JG, Raje N, Cornell RF, Alsina M, Kovacsovics T, Fang B, Kimball AS, Landgren O (2019). Weekly carfilzomib, lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: A phase 1b study. Am J Hematol, 94(7), 794-802.
- Nativi-Nicolau J, Stehlik J, Al-Dulaimi R, Rodriguez C, Jaramillo J, Conte J, Kovacsovics T, Cowley J, Abraham J, Barrel K, Drakos S, Ryan J, Maurer MS, Fang J (2019). Chronotropic incompetence and autonomic dysfunction as mechanisms of dyspnoea in patients with late stage cardiac amyloidosis. Amyloid, 26(sup1), 134-135.
- Ruiz-Negrn N, Nativi-Nicolau J, Maurer MS, Moran AE, Kovacsovics T, Bellows BK (2019). Cost-effectiveness of technetium pyrophosphate scintigraphy versus heart biopsy for the diagnosis of transthyretin amyloidosis. Amyloid, 26(sup1), 71-72.
- Scott EC, Heitner SB, Dibb W, Meyers G, Smith SD, Abar F, Kovacsovics T, Perez-Avraham G, Stentz A, Frires R, Dibb J, Maziarz RT (2014). Induction bortezomib in Al amyloidosis followed by high dose melphalan and autologous stem cell transplantation: a single institution retrospective study. Clin Lymphoma Myeloma Leuk, 14(5), 424-430.e1.
- Cogle CR, Goldman DC, Madlambayan GJ, Leon RP, Masri AA, Clark HA, Asbaghi SA, Tyner JW, Dunlap J, Fan G, Kovacsovics T, Liu Q, Meacham A, Hamlin KL, Hromas RA, Scott EW, Fleming WH (2014). Functional integration of acute myeloid leukemia into the vascular niche. Leukemia, 28(10), 1978-1987.
- Lancet JE, Cortes JE, Hogge DE, Tallman MS, Kovacsovics TJ, Damon LE, Komrokji R, Solomon SR, Kolitz JE, Cooper M, Yeager AM, Louie AC, Feldman EJ (2014). Phase II, multicenter, randomized, open label trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus cytarabine and daunorubicin in patients with untreated AML 60-75 years of age. Blood.
- Tyner JW, Yang WF, Bankhead A 3rd, Fan G, Fletcher LB, Bryant J, Glover JM, Chang BH, Spurgeon SE, Fleming WH, Kovacsovics T, Gotlib JR, Oh ST, Deininger MW, Zwaan CM, Den Boer ML, van den Heuvel-Eibrink MM, OHare T, Druker BJ, Loriaux MM (2013). Kinase pathway dependence in primary human leukemias determined by rapid inhibitor screening. Cancer Res, 73(1), 285-96.
- Dunlap J, Beadling C, Warrick A, Neff T, Fleming WH, Loriaux M, Heinrich MC, Kovacsovics T, Kelemen K, Leeborg N, Gatter K, Braziel RM, Press R, Corless CL, Fan G (2012). Multiplex high-throughput gene mutation analysis in acute myeloid leukemia. Hum Pathol, 43(12), 2167-76.
- Faderl S, Wetzler M, Rizzieri D, Schiller G, Jagasia M, Stuart R, Ganguly S, Avigan D, Craig M, Collins R, Maris M, Kovacsovics T, Goldberg S, Seiter K, Hari P, Greiner J, Vey N, Recher C, Ravandi F, Wang ES, Vasconcelles M, Huebner D, Kantarjian HM (2012). Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial. J Clin Oncol, 30(20), 2492-9.
- Claxton D, Erba HP, Faderl S, Arellano M, Lyons RM, Kovacsovics T, Gabrilove J, Huebner D, Gandhi PJ, Kantarjian H, CLASSIC II Investigators (2012). Outpatient consolidation treatment with clofarabine in a phase 2 study of older adult patients with previously untreated acute myelogenous leukemia. Leuk Lymphoma, 53(3), 435-40.
Letter
- Tantravahi SK, Szankasi P, Khorashad JS, Dao KH, Kovacsovics T, Kelley TW, Deininger MW (2016). A phase II study of the efficacy, safety, and determinants of response to 5-azacitidine (Vidaza®) in patients with chronic myelomonocytic leukemia. [Letter to the editor]. Leuk Lymphoma, 57(10), 2441-4.
- Kelemen K, Kovacsovics T, Braziel R, Corless C, Beadling C, Fan G (2012). RAS mutations in therapy-related acute myeloid leukemia after successful treatment of acute promyelocytic leukemia. [Letter to the editor]. Leuk Lymphoma, 53(5), 999-1002.
Global Impact
Education History
| Chief Resident | Clinique Médicale Thérapeutique, Geneva University Hospital Internal Medicine Chief Resident |
| Residency | Clinique Médicale Thérapeutique, Geneva University Hospital Internal Medicine Resident |
| Postdoctoral Fellowship | University of Lausanne Research Assistant, Institute of Biochemistry Postdoctoral Fellow |
| Professional Medical | University of Geneva Medical School Medicine M.D. |